We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Twitter by Jack Prescott. In this article, we will ...

General Manager and CEO of Junshi Biosciences, Dr. Jianjun ZOU, said, “Toripalimab has made significant strides in its internationalization. As of today, toripalimab has been approved in 35 countries ...

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...

InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing ...

H.C. Wainwright reaffirmed its Buy rating and $8.00 price target for InflaRx NV (NASDAQ:IFRX), following the European ...

A study found that some long COVID patients who took Paxlovid saw improvement. But experts said the research isn't enough to ...

Covid symptoms have largely stayed the same over the last few years: cough, congestion, fever, a sore throat, nausea, ...

In December 2024, BioNTech initiated a global randomized Phase 3 clinical trial ( NCT06712355) evaluating BNT327/PM8002 plus chemotherapy compared to atezolizumab plus chemotherapy in first line ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Five years after the COVID-19 pandemic began, millions who are considered immunocompromised still avoid crowds and even ...

Paxlovid vs placebo reduced COVID-19-related hospitalization and death due to any cause through 28 days, as well as the duration of COVID-19 symptoms.

With this model, researchers may be able to discover antibody drugs capable of targeting a wide range of infectious diseases.